VOYA Investment Management
IKT icon

VOYA Investment Management’s Inhibikase Therapeutics IKT Stock Holding History

VOYA Investment Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.4K Buy
16,934
+3,788
+29% +$6.73K ﹤0.01% 2318
2025
Q4 		$26.9K Hold
13,146
– – ﹤0.01% 2388
2025
Q3 		$21.3K Sell
13,146
-5,609
-30% -$9.72K ﹤0.01% 2436
2025
Q2 		$36.6K Buy
+18,755
New +$36.7K ﹤0.01% 2634

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VOYA Investment Management's IKT Position: Q1 2026 in Review

VOYA Investment Management increased its Inhibikase Therapeutics (IKT) stake by 29% in Q1 2026, buying an estimated $6.73K and bringing the position to 16,934 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2318.

VOYA Investment Management first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. The position peaked at $36.6K in Q2 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • VOYA Investment Management held 16,934 shares of Inhibikase Therapeutics worth $28.4K as of Q1 2026.
  • VOYA Investment Management bought 3,788 Inhibikase Therapeutics shares in Q1 2026, an estimated $6.73K.
  • Inhibikase Therapeutics made up ﹤0.01% of VOYA Investment Management's portfolio in Q1 2026, its #2318 holding.
  • VOYA Investment Management first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • VOYA Investment Management's Inhibikase Therapeutics position peaked at $36.6K in Q2 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on VOYA Investment Management's 13F filing for Q1 2026, filed 12 May 2026.